Abstract
Introduction

39
In the ongoing war between bug and drug, Pseudomonas aeruginosa (PA) is a frequent 40 victor because it rapidly develops new defenses to any drug we generate (31, 41) . This is of 41 grave concern for prevention and spread of infectious disease, and is a significant mystery to 42 bacteriologists. While there are a number of known resistance mechanisms that develop in PA, 43 the mystery stems from how these are rapidly generated and accumulate in a population to 44 quickly form high-level resistance to an antimicrobial drug after exposure. Finding solutions to 45 inhibit the rise of resistance in PA is important because the organism is responsible for chronic 46 lung infection in individuals with cystic fibrosis (CF) (6) and chronic obstructive pulmonary 47 disease (COPD) (13, 15, 28) , and also accounts for nearly 10% of hospital-acquired infections 48 (47, 52) . 49
There is a small set of drugs commonly used to treat PA infection, including ciprofloxacin, 50 tobramycin, gentamicin, ceftazidime and imipenem. While PA has developed varying levels of 51 resistance to each of these, its response to ciprofloxacin is of particular interest because the drug 52 is initially very effective, but PA rapidly acquires high-level resistance rendering the drug 53 impotent. In clinical isolates, approximately 30% of strains now present high-level ciprofloxacin 54 resistance (31) . 55 While there have been many studies of factors involved in ciprofloxacin resistance in PA 56 (e.g. (17, 22, 48) ), the series of steps and molecular mechanisms that initially lead from 57 antibiotic-susceptible cells to drug resistant cells still remain unclear. This presents an obstacle to 58 efforts directed at curbing the emergence of new drug resistant strains, and at prolonging the 59 useful lifespan of existing or newly developed antibiotic drugs. We set out to examine the initial 60 steps leading to ciprofloxacin resistance in PA, to ultimately develop strategies that may 61 DNA sequencing. Whole genome DNA sequencing was performed and will be the focus of a 186 separate manuscript, though we discuss one result from that work here. Briefly, whole genomic 187 DNA samples from wild type PAO1 and a isolated ciprofloxacin resistant PAO1-6 were 188 sequenced using a Roche Genome Sequencer FLX System (454) in the High-Throughput 189
Sequencing Facility at the University of North Carolina. We used P. aeruginosa PAO1 complete 190 genome (version: NC_002516.2; GI: 110645304) as a reference to assemble the genome using 191 the Genome Sequencer-Reference Mapper (Roche). 192
Results
193
Examining the response of PA to 48 hr ciprofloxacin exposure. Starting with wild type PAK 194 and PA01 strains, we assayed the minimal inhibitory ciprofloxacin concentrations (MICs) by 195
Etest to establish a baseline. The resulting MICs were within the expected ranges, with PAK 196 reading at 0.25 µg/ml ciprofloxacin and PAO1 at 0.5 µg/ml ciprofloxacin, corroborating previous 197 research (3). 198
We focused our subsequent kinetic population analyses on PA cultures initially grown to 199 on June 27, 2017 by guest http://aac.asm.org/ Downloaded from stationary phase because these cells were observed in previous experiments and our own to 200 exhibit the greatest ability to survive exposure (2, 24). We examined the population dynamics in 201 response to ciprofloxacin exposure at concentrations ranging from 0.5X to 8X MIC in both of 202 PAO1 and PAK. 203 In each case, after exposure to ciprofloxacin, a significant fraction of the initial population 204 was killed by the drug, which we term as Stage I of the antibiotic response, the "susceptible cell 205 death" phase. This stage is the standard and expected response to an antibiotic exposure, and 206 lasts 6-12 hours as illustrated in Figure 1A and B. This first stage has been well studied, 207 including a microarray analysis of changes in gene expression (7, 9, 20) , changes in protein 208
profiles (5), and a mathematical model of the killing kinetics (49). 209
Following Stage I, in every one of our experiments there was a surviving sub-population of 210 cells that remained after the majority had succumbed to death by ciprofloxacin ( Fig. 1A and B, 211 blue arrows). These cells displayed several characteristics in common with previously 212 characterized drug-tolerant or persistent phenotypes (4, 11, (23) (24) (25) . 213
Previous researchers have noted that "drug-tolerant" cells display little heritability from one 214 generation to the next, indicating that the phenotype is not based on genetic changes or 215 mutations. We examined whether this observation applied to our surviving cells by extracting 216 them at various time points after ciprofloxacin exposure, sub-culturing those without 217 ciprofloxacin, then testing their MICs. Their resulting MIC's were 0.75 µg/ml, slightly elevated 218 from the baseline PAO1 wild-type level of 0.5 µg/ml, but not elevated enough to be considered 219 resistant. We termed this population as Stage II of the antibiotic response due to its similarities to 220 the previously classified drug-tolerant (persister) phenotypes. 221
While the cell populations exposed to the highest levels of ciprofloxacin remained static 222 on June 27, 2017 by guest http://aac.asm.org/ Downloaded from 11 and relatively unchanging over 48hr, we noted that at lower exposure levels a cell population 223 would re-grow starting after about 24hr in PAO1 and 12hr in PAK (Fig. 1A and B) . We tested the 224 heritability of drug-susceptibility for these populations by extraction and sub-culture without 225 ciprofloxacin, followed by another Etest. The sub-cultures taken from these reconstituted 226 populations displayed substantially increased heritable MIC's. For PAK, after 40 hours of 227 exposure at 0.5X of the starting MIC (0.125 µg/ml), its population reconstituted to > 10 8 viable 228 cells/ml, and its heritable resistance increased by 8 fold to an MIC of 2 µg/ml (e.g. inset, Fig.  229 1B). For PAO1, after 48 hours of ciprofloxacin exposure at 2X of the starting MIC (0.5 µg/ml), 230 its population reconstituted to > 10 8 viable cells/ml, and its heritable resistance increased by fold to an MIC of 8 µg/ml. Clearly these are a different type of cell than those we defined as experiments with large pre-grown cultures of PA. We started with a 50 ml stationary phase PAO1 243 culture of 10 9 cells/ml that was concentrated to 1 ml (~5x10 10 cells/ml), then plated these directly 244 on a series of six LA plates, each impregnated with 1 µg/ml ciprofloxacin (2X MIC). After 24 245
on June 27, 2017 by guest http://aac.asm.org/ Downloaded from 12 hours incubation on the ciprofloxacin-LA plates, we scraped the cells for resuspension in 3 ml 246 fresh LB, then grew them overnight. We then assayed the culture's MIC by Etest and they were 247 in the range of 0.5-0.75 µg/ml, showing no evidence for the pre-existence of a cell in the culture 248 with substantially elevated resistance. 249
The distribution of ciprofloxacin resistance across distinct colonies. We started with a 50 ml 250 liquid culture of PAK grown to stationary phase, then collected 1 ml aliquots both before 251 ciprofloxacin exposure and after 6 and 20 hours exposure (with 0.5X of the starting MIC; 0.125 252 µg/ml). The washed and diluted cells were plated separately according to time point, and grown 253 overnight on LA medium (without ciprofloxacin). We randomly isolated 96 distinct colonies 254 from each of the distinct time point plates, transferring them individually into wells on a 96-well 255 microtiter plate to measure their resultant pre-or post-exposure MICs. For each time point, the 256 measured MIC distribution was heterogeneous ( Fig.2 A) , and could be approximately modeled 257 with a normal distribution (Fig. 2 B) . As ciprofloxacin exposure time increased, the mean of the 258 MIC distribution shifted higher, with the fitted normal distributions showing mean MICs rising 259 from 0.29 µg/ml at 0 hours to 0.63 µg/ml after 20-h, and their standard deviations increasing 260 from 0.08 µg/ml at 0-h to 0.21 µg/ml at 20-h. After 20 hours of ciprofloxacin exposure, a few 261 selected colonies displayed at least 4-fold increase from the starting MIC, to > 1 µg/ml, and 262 many displayed more than 2-fold increase. These data indicate that the mechanism(s) underlying 263
Stage III resistance are activated in varying degrees throughout the population after ciprofloxacin 264 exposure, not as a binary on/off resistance. tolerant/persistent (N), and resistant (R). We used the model to examine the question of whether 270 resistant cells R pre-exist in the population at the time of ciprofloxacin exposure, or whether they 271 develop resistance after exposure. In the initial model provided by Levin, the presence of one 272 resistant cell per ml at time t=0 (ciprofloxacin exposure) was assumed, with the resistant cell(s) 273 having MIC=20 µg/ml (40X the MIC of the susceptible cells PAO1). Experiments were run 274 assuming ciprofloxacin concentrations from 0-4 µg/ml, and mutation rates as low as 10 -18 . 275
Regardless of mutation rate, for antibiotic concentrations A ≤ 4 µg/ml, the population recovered 276 to 10 8 cells/ml in under 27 hours ( Fig. 3 A) , with a high slope of recovery. Comparing the A=2 277 µg/ml results from the model to the in vitro experiments at the same concentration, the model's 278 population recovered much more quickly than the live cells. 279
In order to produce a model whose population recovered at the slower timeframe shown in 280 vitro, we had to remove the assumption that there were initially resistant cells in the population, 281 by setting the initial resistant population R < 10 -6 cells/ml. We then adjusted the mutation rates 282 for various simulations, and the models whose populations recovered on a timescale most similar 283 to the lab experiments had mutation rates to lie in between 10 -9 and 10 -8 . These simulations agree 284 with our solid media experiments to indicate resistant cells were not likely present, nor are they 285 necessary, to reproduce the in vitro population recover results we observed. These stage III cells had a new MIC of 2 µg/ml, an 8X increase over wild type, and we hereafter 293 refer to them as PAK-F5. We analyzed extracted protein samples from two independent 294 biological replicates by multiplexed 2D-GE (43). We stained the proteins in the gels for 295 phosphoprotein abundance (Pro-Q Diamond) and for total protein abundance (SYPRO Ruby). 296
Of the approximately 650 protein spots observed on the gels, three proteins displayed 297 visually identifiable and repeatable differences in expression between PAK-F5 and unexposed 298 wild type cells. Two of those were differentially phosphorylated, having a 4-fold increase in the 299 ratio of phosphorylated to total protein (Fig. 4) for PAK-F5 cells versus wild-type. 300
These proteins were identified by mass spectrometry as PA0265 (succinate-semialdehyde 301 dehydrogenase or SSADH, encoded by gabD) and PA3570 (methylmalonate-semialdehyde 302 dehydrogenase or MMSADH, encoded by mmsA). Surprisingly, neither of these had been 303 previously identified as phosphoproteins in PA. They are putatively involved in amino acid 304 metabolism and/or energy production (46). A third protein displayed 6-fold higher total protein 305 abundance in PAK-F5. It was identified by mass spectrometry as PA3539, a conserved 306 hypothetical protein of unknown function, encoded by the gene yaaA (see Table S1 (Table S2 in the supplementary materials). The phoU control mutant was chosen because a 316 homologous protein was previously implicated in the formation of the persister phenotype (Stage 317 II) in E. coli (27). The gatA control was chosen because its protein was visible on the same 318 proteomic gels as the identified proteins, yet appeared unchanged in expression between wild-319 type and resistant strains. 320
We determined the starting MICs for each mutant, then assessed their population kinetics 321 after ciprofloxacin exposure at 2X, 4X and 8X of their starting MICs. The mutant strains 322 displayed a Stage II surviving population ratio similar to wild-type and mutant controls (Fig. 5A,  323 bottom panel and Fig. S1 in the supplemental material). However, the ability to reconstitute a 324
Stage III population in the continuing presence of ciprofloxacin was substantially muted by gene 325 disruption (Fig. 5A , top panel, and see Fig. S1 ). The differences between strains were most 326 apparent at 4X of the starting MICs. The control mutants did not have a similarly negative effect 327 on Stage III population recovery. 328
We then studied whether the ability to develop heritable resistance in the mutants (Stage III) 329 was inhibited. Each of the wild-type PAO1, control, and candidate strains were exposed to 4X 330 and 8X of the starting MIC concentrations of ciprofloxacin in liquid culture for 24 and 48 331 hours. In wild-type PAO1, resistance increased 50-fold to a clinically significant level, following 332 48 hrs exposure at 4X of the starting MIC (Fig. 5B) . In the gatA control mutant, the result was 333 very similar. The phoU control mutant showed reduced resistance compared to the wild-type 334 after 8X MIC ciprofloxacin exposure, but at 4X exposure resistance developed to about 35X of 335 its starting MIC. 336
In contrast to both controls, each of the Stage III associated mutant strains showed dramatic 337 on June 27, 2017 by guest http://aac.asm.org/ Downloaded from 16 decreases in the development of heritable resistance after exposure at both 4X and 8X of the 338 starting MIC. None of them achieved a clinically significant drug-resistance level. The resistance 339 inhibition was strongest with the mmsA mutant. 340
We measured whether the reduced ability of the candidates to survive exposure was due to a 341 pleiotropic growth defect. The candidate mutants did not present any significant growth defects 342 prior to ciprofloxacin exposure (Fig S2) . Growth defects were only apparent after ciprofloxacin 343 exposure, upon Stage III recovery. 344
The effect of culture size on Stage III development. In wild type PA, we observed that the 345 development of Stage III resistance and the resulting population recovery was affected by culture 346 volume (i.e. population size) and ciprofloxacin concentration (see Fig. S3 A and B in the 347 supplemental material). Examining this in detail, we measured PAO1 ciprofloxacin kill/re-348 growth curves in liquid culture volumes of 5, 25 and 50 ml, at both 2X and 4X of the starting 349
MIC. 350
At 2X of the starting MIC, there was a clear recovery of the population with Stage III 351 resistance, regardless of culture volume (see Fig. S3 A, in the supplemental material). However, 352 at 4X of the starting MIC, only the 50 ml culture reconstituted (see Fig. S3 B) . This result can be 353 explained by our model of a normal distribution for MICs in the population (Fig. 2) . 354 Depending on both the exposure level and population size, there may or may not be enough 355 cells that develop Stage II resistance above that survival threshold to reconstitute the population 356 (e.g. Fig. 6 ). From the experiment shown in Fig. S3 A and B representing the fluoroquinolones, β-lactams, and aminoglycosides (see Table S3 growing, and do not display significantly increased MIC levels. Finally, after continuous 371 exposure at moderate ciprofloxacin levels (< 8X MIC), a Stage III population arises that is 372 rapidly growing and exhibit substantially increased MIC levels. While a process of mutation 373 appears to underlie the Stage III cells (data to be reported separately), it appears that non-genetic 374 regulatory mechanisms may also play an important role in the resistance phenotype. In the PAK-375 F5 strain we identified three significantly altered proteins, two of which appear to have an effect 376 via phosphorylation, appear to be essential for the development of Stage III. 377
We naturally wondered how these results could be related to previous studies that have 378 shown a gyrA mutation as one primary molecular mechanism for ciprofloxacin resistance in PA 379 is evidence that changes to other genes such as parC, and efflux pump regulator, are necessary to 385 produce high-level ciprofloxacin resistance in P. aeruginosa (16, 32, 51) . 386
The multi-stage process of ciprofloxacin resistance in PA that we illustrate here raises a 387 significant question: does the Stage III resistant exist in the population before the bacteria are 388 exposed to the ciprofloxacin? One reason for thinking this is because the population sizes are 389 vastly larger before exposure to ciprofloxacin than after. It might be argued that mutations would 390 be improbable to arise out of the relatively small Stage II population to produce Stage III. 391
Yet the evidence all points to a different scenario: that the mutation(s) and regulatory 392 changes evidenced in Stage III arise directly from the Stage II population -not from a pre-393 existing mutant in the population. It also indicates that the process is stepwise and 394 heterogeneous, not a single, large jump to a higher resistance level. While this result is surprising 395 when considered in the context of current theories, there is support for higher mutation rates in 396 ciprofloxacin-exposed cells via the SOS response (29). When mutation rates are increased 397 artificially via a mutS deletion, PAO1 can develop high-level ciprofloxacin resistance on the 398 order of 1 in 10 6 cells per generation (35) . 399 This is compatible with our results that demonstrated a required volume of cells over 20 ml 400 to develop Stage III resistance. The Stage II population are present at 10 4 to 10 5 cells per ml, and 401 therefore, at vol=20 ml, we had totcells≈10 6 in the culture. If we speculate that mutation of a 402 tolerant cell to a resistant cell is occurring at a rate of mur=10 
